A5075740717- Hair Growth and Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Dermatology and Skin Diseases
- Renal Diseases and Glomerulopathies
- Adolescent and Pediatric Healthcare
- Autoimmune Bullous Skin Diseases
- Atherosclerosis and Cardiovascular Diseases
- Chronic Kidney Disease and Diabetes
- Eosinophilic Disorders and Syndromes
- melanin and skin pigmentation
- Inflammatory Myopathies and Dermatomyositis
- Sarcoma Diagnosis and Treatment
- Social Media in Health Education
- Health Literacy and Information Accessibility
- Systemic Lupus Erythematosus Research
- Delphi Technique in Research
- Healthcare cost, quality, practices
- Myofascial pain diagnosis and treatment
- Health, psychology, and well-being
- Skin Protection and Aging
- Complement system in diseases
- Spinal Dysraphism and Malformations
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Patient-Provider Communication in Healthcare
- Medication Adherence and Compliance
Pfizer (United States)
2020-2024
Tris Pharma (United States)
2015-2024
Impact Technology Development (United States)
2020-2021
RTI Health Solutions
2016
Novartis (United States)
2015
Ithaka Harbors
2014
United BioSource Corporation (United Kingdom)
2011-2012
Johannes Gutenberg University Mainz
2012
Health Outcomes Solutions (United States)
2010
Brepocitinib is a TYK2/JAK1 inhibitor in development for the treatment of several immunologic diseases. The efficacy and safety oral brepocitinib were assessed participants with moderately-to-severely active psoriatic arthritis (PsA) up to 52 weeks.In this placebo-controlled, dose-ranging, phase IIb study, randomized receive 10 mg, 30 or 60 mg once daily placebo, advancing at week 16. primary endpoint was response rate according American College Rheumatology criteria 20% improvement (ACR20)...
Alopecia areata (AA) is a chronic, autoimmune disease of hair loss, which can significantly affect the emotional and psychological well-being patients. A systematic literature review was conducted to better understand burden AA from patient perspective. Embase, MEDLINE Cochrane databases were searched for published studies (2008–2018) reporting on assessments health-related quality life (HRQoL) patients with AA. Qualitative, quantitative data collected. The included 37 encompassing range...
The phase 2a ALLEGRO trial (NCT02974868) investigated the safety and efficacy of ritlecitinib (PF-06651600) brepocitinib (PF-06700841) in adults with alopecia areata. No randomized controlled for areata has evaluated correlations between clinician-assessed hair loss patient-reported outcomes.Report scores from Alopecia Areata Symptom Impact Scale (AASIS; a outcome tool) explore relationships those Severity Tool (SALT) at baseline week 24 trial.Adults were to (n = 48), 47) or placebo 47)....
Individuals with alopecia areata (AA) may experience significant impacts on their health-related quality of life. The novel Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire has been developed to assess hair loss signs, emotional symptoms, and activity limitations associated AA. objective this study was evaluate psychometric properties establish scoring the AAPPO in adults adolescents AA.Scoring measurement were examined using baseline 2-week follow-up data from a prospective,...
Although alopecia areata (AA) profoundly impacts patients' physical appearance, emotional state, and daily activities, no treatment approved for AA currently exists. Patient-reported outcome (PRO) instruments used to capture experiences do not meet the requirements support claims of benefit as described in US Food Drug Administration's 2009 PRO guidance. Our objective was explore consequences priority outcomes among individuals with develop a measure consistent regulatory that assesses these...
Background and purpose To investigate resource use burden associated with spina bifida ( SB ) in Germany. Methods A questionnaire was used to obtain information on ‐related healthcare assistive technologies for the last 1 10 years. Individuals were recruited at a tertiary specialist clinic. participate, persons required cognitive ability respond or caregiver answer questions their behalf. They could personal medical charts other records answer. The analyses included assessment of frequency...
Dermatomyositis (DM) is a rare systemic autoimmune disease characterized by distinctive debilitating skin rash and skeletal muscle weakness. It unclear if existing clinical outcome assessment (COA) measures include the concepts of priority to patients those necessary fully capture improvements in active cutaneous manifestations DM. This study aimed develop Cutaneous Investigator Global Assessment (CDM-IGA), de novo IGA, for use trials adult
Background: Neural Tube Defects (NTDs) are serious birth defects of which Spina Bifida (SB) is the most common.This paper aims to provide an estimate burden illness for patients with SB and their caregivers in Canada, assess benefit primary prevention.Methods: Individuals NTDs were recruited through a hospital Toronto.Using clinic's database, individuals screened confirm eligibility.Data collected using three types questionnaires: sociodemographic, resource use Quality Life (QoL).Results: Of...
Patient experience literature in early-stage breast cancer (eBC) is limited. This study used a mixed-methods approach to examine patient conversations from public online forums identify and evaluate eBC-related themes. Among 60,000 posts published September 2014-2019, text random subset of 15,000 was extracted grouped into linguistically similar, mutually exclusive clusters using an advanced natural language processing (NLP) algorithm. Clusters were characterized four quantitative metrics:...